Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis

Inclusion criteria

18 < Age < 80

AF diagnosed by ECG at any time prior to enrollment

Moderate or severe mitral valve stenosis diagnosed by echocardiography at any time prior to enrollment

Exclusion criteria

Refusal to consent

Transient AF due to reversible cause (Postoperative, ongoing systemic inflammation, thyrotoxicosis)

Patients undergoing mechanical valve replacement

Coagulopathy

Hepatic impairment with significant bleeding risk

High bleeding risk due to following disease or condition diagnosed within 1 month prior to randomization

GI ulcer or bleeding, Esophageal or gastric varix, Malignancy, Brain or cord injury, Surgery for brain, spinal cord, opthalmic, Intracranial hemorrhage, Arteriovenous malformation, Vascular aneurysms, Brain or spinal vascular disorder

Stroke, Systemic arterial thromboembolism, Acute myocardial infarction diagnosed within 14 days prior to randomization

End stage kidney disease (CrCL < 15mL/min) or Dialysis

Severe hypertension

Alcohol abuse or other psychiatric disease

Epidural puncture or anesthesia

Pulmonary thromboembolism with hemodynamical instability requiring thrombolysis or thrombectomy

Pregnant or lactating women

Allergy to edoxaban or warfarin

Ongoing need for other anticoagulant or clarithromycin, rifampin)

Participants for other trials within 1 month prior to enrollment

Other patients to be inappropriate to participate in the trial determined by the investigator